Invega

Schizophrenia in adolescents ≥15 yr including acute treatment & recurrence prevention. Acute exacerbations of schizoaffective disorder as monotherapy & in combination w/ antidepressants &/or mood stabilizers.

Schizophrenia Adult ≥18 yr 6 mg once daily. Max: 12 mg daily. Recommended range: 3-12 mg once daily. Adolescent 15-17 yr 3 mg once daily in the morning, <51 kg Max: 6 mg daily, ≥51 kg Max: 12 mg daily. Schizoaffective disorder 6 mg once daily in the morning. Max: 12 mg daily. Recommended range: 3-12 mg once daily. Mild renal impairment (CrCl ≥50 to <80 mL/min) Initially 3 mg once daily, may be increased to 6 mg once daily. Moderate to severe renal impairment (CrCl ≥10 to <50 mL/min) Max: 3 mg once daily.

May be taken with or without food: Swallow whole, do not chew/divide/crush.

Hypersensitivity to paliperidone or risperidone.

Discontinue use if NMS or tardive dyskinesia/extrapyramidal symptoms occur. History of cardiac arrhythmias, congenital long QT syndrome; hyperglycemia & DM; wt gain; known CV or cerebrovascular disease or conditions predisposing to hypotension; seizures or conditions lowering seizure threshold; preexisting severe GI narrowing or dysphagia or significant difficulty in swallowing; clinically significant low WBC or drug-induced leukopenia/neutropenia; risk factors for VTE; Parkinson's disease & dementia w/ Lewy bodies; priapism. Intraoperative floppy iris syndrome. Antiemetic effect. Conditions that contribute to core body temp elevation or dehydration. Concomitant use w/ risperidone; psychostimulants eg, methylphenidate; drugs prolonging QT interval. May affect ability to drive & use machines. Severe hepatic & renal impairment (CrCl <10 mL/min). Pregnancy. Not to be used during lactation. Adolescents & childn <12 yr w/ schizophrenia; adolescents & childn <18 yr w/ schizoaffective disorder. Elderly w/ dementia.

Headache, akathisia, somnolence, tremor, cogwheel rigidity; insomnia; vomiting, nausea.

Antagonized effect of l-dopa & other dopamine agonists. Decreased mean steady-state C_max & AUC w/ carbamazepine. Increased C_max & AUC w/ divalproex Na. Emergence of extrapyramidal symptoms w/ psychostimulants eg, methylphenidate. Concomitant use w/ drugs prolonging QT interval; centrally-acting drugs, alcohol.

Antipsychotics

N05AX13 - paliperidone ; Belongs to the class of other antipsychotics.

B